| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1122 | |
| Phytochemical name or plant extracts | 2-Methoxyestrone | |
| PMID | 30037062 | |
| Literature evidence | Compounds (2), (3), and (4) are potential candidates for novel anti-cancer agents against breast and colorectal cancers. | |
| IUPAC name | (8R,9S,13S,14S)-3-hydroxy-2-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one | |
| Phytochemicals’ class or type of plant extracts | Steroid glucosiduronic acid | |
| Source of phytochemicals or plant Extracts | Imperata cylindrica | |
| Geographical availability | Afghanistan, Albania, Algeria, Angola, Baleares, Benin, Botswana, Bulgaria, Burkina, Burundi, Cameroon, Canary Is., Cape Provinces, Cape Verde, Central African Repu, Chad, Comoros, Congo, Corse, Cyprus, East Aegean Is., Egypt, Equatorial Guinea, Ethiopia, France, Free State, Gabon, Gambia, Ghana, Greece, Guinea, Guinea-Bissau, Gulf of Guinea Is., Iran, Iraq, Italy, Ivory Coast, Kenya, Kriti, Kuwait, KwaZulu-Natal, Lebanon-Syria, Lesotho, Liberia, Libya, Madagascar, Madeira, Malawi, Mali, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Northern Provinces, Oman, Palestine, Portugal, Rwanda, Sardegna, Saudi Arabia, Senegal, Sicilia, Sierra Leone, Sinai, Socotra, Spain, Sudan, Swaziland, Tanzania, Togo, Tunisia, Turkey, Turkey-in-Europe, Uganda, Yemen, Yugoslavia, Zambia, Zaïre, Zimbabwe | |
| Plant parts | Aerial parts | |
| Other cancers | Breast cancer, Colon cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | At 48h, 72h: 43 µg/mL, 31 µg/mL against BT-549 respectively | |
| Potency | Imperata cylindrica (L.) Raeusch., one kind of traditional herbal medicine, has rational medical application potentials with respect to breast and colorectal cancer prevention. | |
| Cell line/ mice model | BT-549, HT-29 | |
| Additional information | 2-Methoxyestrone, is one kind of metabolite of estrone and estradiol. It is worth mentioning that 2-Methoxyestradiol was under a phase II clinical trial and expected to be a novel oral drug against multiple human melanoma, including breast cancer and ovarian cancer | |
| PubChem ID | 440624 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:30138371-2 | |
| Safety | NA |